New Study Reveals Anti-Cancer Properties In Kencur Ginger

Translate to Spanish or other 102 languages!

While previous studies on EMC indicated its anti-cancer potential by decreasing the expression of mitochondrial transcription factor A (TFAM), which is associated with cancer cell proliferation, the exact mechanism remained unclear until now. Image source Ginger: Facebook for illustration purposes
While previous studies on EMC indicated its anti-cancer potential by decreasing the expression of mitochondrial transcription factor A (TFAM), which is associated with cancer cell proliferation, the exact mechanism remained unclear until now. Image source Ginger: Facebook for illustration purposes

Mega Doctor News

- Advertisement -

BOsaka Metropolitan University

You may know it as an aromatic spice to add flavor to your dishes or as a soothing herbal remedy to use for upset stomachs, but researchers from Osaka Metropolitan University have uncovered promising findings that Kencur, a tropical plant in the ginger family native to Southeast Asia, possesses anti-cancer effects.

Led by Associate Professor Akiko Kojima of the Graduate School of Human Life and Ecology, the researchers demonstrated that Kencur extract and its main active component, ethyl p-methoxycinnamate (EMC), significantly suppressed cancer cell growth at the cellular and animal levels.

- Advertisement -

While previous studies on EMC indicated its anti-cancer potential by decreasing the expression of mitochondrial transcription factor A (TFAM), which is associated with cancer cell proliferation, the exact mechanism remained unclear until now.

“The results of this study confirm the anti-cancer effects of Kencur extract and its main active ingredient, EMC. It is highly expected that TFAM will become a new marker for anti-cancer effects in the future as research advances in related fields,” Professor Kojima stated.

Their findings were published in Heliyon.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

Physicians Warn of Rising ER Visits Linked to E-Bikes and Scooters

Mega Doctor News CLEVELAND CLINIC - As electric bikes and scooters grow in...

How Anthocyanins Give Blueberries Their Superfood Status

If you like blueberries, or have been thinking about trying them, you may be surprised to know this tiny fruit offers some big health benefits.

Endocrine Society Outlines Strict Rules for Safe Testosterone Therapy

The Society’s Clinical Practice Guideline on testosterone replacement therapy in men with hypogonadism offers recommendations on appropriate testing and prescribing practices. 
- Advertisement -